Growth Metrics

Soleno Therapeutics (SLNO) EBITDA (2016 - 2025)

Soleno Therapeutics (SLNO) has disclosed EBITDA for 9 consecutive years, with $43.4 million as the latest value for Q4 2025.

  • For Q4 2025, EBITDA changed N/A year-over-year to $43.4 million; the TTM value through Dec 2025 reached $20.9 million, changed N/A, while the annual FY2025 figure was $20.9 million, 111.93% up from the prior year.
  • EBITDA hit $43.4 million in Q4 2025 for Soleno Therapeutics, up from $26.3 million in the prior quarter.
  • Across five years, EBITDA topped out at $43.4 million in Q4 2025 and bottomed at -$43.9 million in Q1 2025.